<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01887119</url>
  </required_header>
  <id_info>
    <org_study_id>133031</org_study_id>
    <nct_id>NCT01887119</nct_id>
  </id_info>
  <brief_title>Aldosterone Antagonism and Microvascular Function</brief_title>
  <official_title>Effects of Aldosterone Antagonism on Insulin-mediated Microvascular Function in Subjects With the Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of obesity and obesity-related complications is currently taking epidemic&#xD;
      proportions. These complications increase the risk of type 2 diabetes and cardiovascular&#xD;
      disease, which are important causes of morbidity and mortality worldwide.&#xD;
&#xD;
      It is important to gain insight in the mechanisms underlying obesity-related complications,&#xD;
      because this may lead to the development of directed therapeutic strategies.&#xD;
&#xD;
      Currently, there is significant evidence that the cause of both insulin resistance and&#xD;
      hypertension must be sought at the level of the microcirculation.&#xD;
&#xD;
      Over activity of the renin-angiotensin-aldosterone system is a potential cause of&#xD;
      microvascular dysfunction. Angiotensin II was indeed found to be implicated in the&#xD;
      pathogenesis of obesity-associated hypertension and insulin resistance, possibly through&#xD;
      interference with the vascular effects of insulin.&#xD;
&#xD;
      Increased aldosterone levels have also been associated with resistant hypertension and&#xD;
      insulin resistance, which is illustrated in patients with primary aldosteronism. Furthermore,&#xD;
      aldosterone is known to exert several detrimental effects on the vasculature, some of which&#xD;
      are offset by mineralocorticoid receptor antagonists.&#xD;
&#xD;
      In obese individuals, plasma aldosterone concentrations are increased as well. We hypothesize&#xD;
      that increased aldosterone levels in adipose persons induce microvascular dysfunction, which&#xD;
      contributes to the development of insulin resistance and hypertension, and mineralocorticoid&#xD;
      receptor antagonism results in improved insulin sensitivity and decreased blood pressure by&#xD;
      counteracting the adverse effects of aldosterone on the microvasculature.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Failure to recruit sufficient participants&#xD;
  </why_stopped>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Actual">November 2018</completion_date>
  <primary_completion_date type="Actual">November 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in capillary recruitment (insulin-induced increase in microvascular blood volume in skeletal muscle) from baseline after 4 weeks of Eplerenone treatment or placebo</measure>
    <time_frame>Change from baseline after 4 weeks of treatment with either Eplerenone or placebo</time_frame>
    <description>The difference in microvascular blood volume in skeletal muscle of the forearm, which is assessed with contrast enhanced ultrasound, before and during a hyperinsulinemic, euglycemic clamp (performed to determine insulin sensitivity)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Abdominal Obesity Metabolic Syndrome</condition>
  <condition>Insulin Resistance</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Eplerenone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eplerenone 50 mg 1dd during four weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eplerenone-matched placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <arm_group_label>Eplerenone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Eplerenone-matched placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 40-65 years&#xD;
&#xD;
          -  Caucasian&#xD;
&#xD;
          -  Waist circumference &gt; 102 cm (men)/&gt; 88 cm (women)&#xD;
&#xD;
          -  Triglycerides &gt; 1.7 mmol/L&#xD;
&#xD;
          -  High-normal blood pressure (office blood pressure: 130/85 - 139/89 mm Hg) or stage I&#xD;
             hypertension (office blood pressure: 140/90 mm Hg - 159/99 mm Hg; 24h ABPM: 125/80 -&#xD;
             149/89 mm Hg)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease,&#xD;
             congestive heart failure, cardiac shunts, cardiac surgery, pulmonary hypertension,&#xD;
             cardiac arrhythmias, family history of cardiac arrhythmias or sudden cardiac death)&#xD;
&#xD;
          -  Diabetes mellitus/impaired glucose metabolism (fasting glucose values &gt; 5.6 mmol/L)&#xD;
&#xD;
          -  Grade 2 or 3 hypertension (office blood pressure: &gt; 160/100 mm Hg; ABPM &gt; 150/90 mm&#xD;
             Hg)&#xD;
&#xD;
          -  Unstable or severe pulmonary disease&#xD;
&#xD;
          -  Unstable or severe thyroid disorders&#xD;
&#xD;
          -  Inflammatory diseases&#xD;
&#xD;
          -  Alcohol use &gt; 2 U/day (women)/&gt; 3 U/day (men)&#xD;
&#xD;
          -  Use of antihypertensive, lipid-lowering or glucose-lowering medications,&#xD;
&#xD;
          -  Use of corticosteroids, medication known to inhibit or induce CYP3A4, lithium, and&#xD;
             tricyclic antidepressants or antipsychotic medication, and regular use (weekly or&#xD;
             several times a week) of NSAIDs&#xD;
&#xD;
          -  Plasma potassium levels &lt; 3.2 mmol/L or &gt; 5 mmol/L&#xD;
&#xD;
          -  eGFR &lt; 60 mL/min&#xD;
&#xD;
          -  Impairment of hepatic function&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>prof. C.D.A. Stehouwer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>June 19, 2013</study_first_submitted>
  <study_first_submitted_qc>June 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2013</study_first_posted>
  <last_update_submitted>November 1, 2018</last_update_submitted>
  <last_update_submitted_qc>November 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maastricht University Medical Center</investigator_affiliation>
    <investigator_full_name>Monica Sch√ºtten</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Obesity, Abdominal</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

